Automated Insulin Delivery Systems Are Now Recommended for Some People With Type 2 Diabetes

For decades, automated insulin delivery systems have been a cornerstone of care for people with type 1 diabetes. Now, updated clinical guidelines recognize that some adults with type 2 diabetes can also benefit from this technology. The shift reflects growing evidence that AID systems address real challenges many people face when managing insulin therapy.

Many adults with type 2 diabetes struggle to reach their blood sugar targets, even with insulin treatment. Two major obstacles often get in the way: fear of low blood sugar episodes and the complexity of managing multiple daily insulin injections. These barriers can lead to therapeutic inertia—a pattern where people and providers delay or avoid intensifying treatment, even when it's needed.

Both randomized controlled trials and real-world studies demonstrate that AID systems deliver meaningful improvements for people with type 2 diabetes who need insulin. The systems improve A1C levels—a key measure of average blood sugar over three months—while also increasing time in range, the percentage of time blood sugar stays in a safe, target zone.

Importantly, these benefits come without increasing hypoglycemia (low blood sugar episodes). The systems work by continuously reading glucose data and automatically adjusting insulin delivery in real time, which means less manual decision-making and fewer opportunities for error.

According to updated guidelines, AID systems are now the preferred insulin delivery method for adults with type 2 diabetes who are on multiple daily injections or who cannot reach their targets with basal insulin alone (the long-acting background insulin).

By automating insulin adjustments, these systems reduce the burden of daily management and help people overcome the fear of hypoglycemia that often prevents them from using enough insulin to meet their needs. Remote monitoring also allows healthcare teams to review glucose data and adjust treatment plans without requiring frequent office visits.

The recognition of AID as a preferred option for some people with type 2 diabetes represents a significant shift in how providers think about insulin therapy. Rather than viewing it as a last resort, these systems are now seen as a practical strategy to help people overcome barriers, achieve better control, and reduce the burden of daily diabetes management.

If you have type 2 diabetes and are considering insulin therapy, or if you're already on insulin and struggling to reach your targets, this may be worth discussing with your healthcare team.

Source: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.